microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13192
Abstract: Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of… read more here.
Keywords: cellular senescence; gemcitabine; gemcitabine resistant; bladder cancer ... See more keywords
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13279
Abstract: Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine is essential for precision therapy of PDAC. However, existing quantitative signatures of… read more here.
Keywords: gps; resistance; gemcitabine; adenocarcinoma ... See more keywords
In Situ Formed ROS-responsive Hydrogel with STING Agonist and Gemcitabine to Intensify immunotherapy Against Pancreatic Ductal Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202203264
Abstract: Immunotherapy, the most revolutionary anticancer strategy, faces major obstacles in yielding desirable outcomes in pancreatic ductal adenocarcinoma (PDAC) due to the highly immunosuppressive tumor microenvironment (TME). Meanwhile, when used alone, the traditional first-line chemotherapeutic agent… read more here.
Keywords: sting agonist; immunotherapy; hydrogel; ductal adenocarcinoma ... See more keywords
Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer medicine"
DOI: 10.1002/cam4.4590
Abstract: INTRODUCTION Gemcitabine is a well-known radiosensitizer. Herein, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer. PATIENTS AND METHODS This was a phase II, single-arm trial.… read more here.
Keywords: advanced rectal; gemcitabine; infusional gemcitabine; locally advanced ... See more keywords
Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5147
Abstract: Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single‐agent in a larger series of patients with advanced angiosarcoma. We retrospectively… read more here.
Keywords: single agent; patients advanced; agent gemcitabine; gemcitabine ... See more keywords
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5971
Abstract: BACKGROUND Neoadjuvant treatment with nab-paclitaxel and gemcitabine for potentially operable pancreatic adenocarcinoma has not been well studied in a prospective interventional trial and could down-stage tumors to achieve negative surgical margins. METHODS A single-arm, open-label… read more here.
Keywords: node positive; nab paclitaxel; borderline resectable; gemcitabine ... See more keywords
Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity
Sign Up to like & getrecommendations! Published in 2017 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12113
Abstract: Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side effects. We describe a case of a 67‐year‐old woman with follicular lymphoma who experienced a rarely… read more here.
Keywords: gemcitabine; case; multiple hit; cardiotoxicity ... See more keywords
EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R‐GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.97_2631
Abstract: *Was employed by DRG Abacus at the time of analysis **Was employed by F. Hoffmann-La Roche Ltd at the time of the analysis Background: Despite improvements in DLBCL treatment, outcomes for patients with R/R DLBCL… read more here.
Keywords: sct ineligible; network; gemcitabine; analysis ... See more keywords
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33225
Abstract: In a previous phase II study (THERAPY), cetuximab and trastuzumab combination, as second‐line after progression with gemcitabine, showed disease stabilization in 27% of 33 patients with pancreatic carcinoma. In the present phase II multicenter study,… read more here.
Keywords: phase; line; gemcitabine; treatment ... See more keywords
Everolimus Inhibits Growth of Gemcitabine‐Resistant Pancreatic Cancer Cells via Induction of Caspase‐Dependent Apoptosis and G2/M Arrest
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.25921
Abstract: Pancreatic cancer is the fourth leading cause of cancer‐related death in the United States. While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced pancreatic cancer, its resistance is a large obstacle in the field.… read more here.
Keywords: everolimus; gemcitabine; resistant pancreatic; pancreatic cancer ... See more keywords
Metformin‐induced alterations in nucleotide metabolism cause 5‐fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.26291
Abstract: 5‐Fluorouracil (5‐FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5‐year mortality rate exceeds 85%. Our study investigated the effects of metformin,… read more here.
Keywords: gemcitabine; metformin; resistance; nucleotide metabolism ... See more keywords